XLO: Xilio Therapeutics Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Xilio Therapeutics Inc (XLO).
$41.98M Market Cap.
XLO Market Cap. (MRY)
XLO Shares Outstanding (MRY)
XLO Assets (MRY)
Total Assets
$71.08M
Total Liabilities
$53.48M
Total Investments
$0
XLO Income (MRY)
Revenue
$6.34M
Net Income
-$58.24M
Operating Expense
$66.93M
XLO Cash Flow (MRY)
CF Operations
-$18.38M
CF Investing
-$36.00K
CF Financing
$29.20M
XLO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $71,075,000 (16.66%) | $60,926,000 (-56.22%) | $139,165,000 (-36.18%) | $218,060,000 (500.44%) |
Assets Current | $60,234,000 (25.16%) | $48,127,000 (-61.34%) | $124,496,000 (-38.53%) | $202,517,000 (883.57%) |
Assets Non-Current | $10,841,000 (-15.30%) | $12,799,000 (-12.75%) | $14,669,000 (-5.62%) | $15,543,000 (-1.17%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $17,598,000 (-52.21%) | $36,827,000 (-65.14%) | $105,647,000 (-43.03%) | $185,429,000 (322.64%) |
Property Plant & Equipment Net | $9,059,000 (-18.14%) | $11,067,000 (-13.81%) | $12,840,000 (-5.57%) | $13,597,000 (-0.58%) |
Cash & Equivalents | $57,073,000 (23.29%) | $46,291,000 (-62.04%) | $121,947,000 (-38.91%) | $199,606,000 (860.15%) |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Deferred Revenue | $32,780,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $2,574,000 (145.14%) | $1,050,000 (-66.40%) | $3,125,000 (-0.60%) | $3,144,000 (-42.25%) |
Accumulated Retained Earnings (Deficit) | -$383,753,000 (-17.89%) | -$325,512,000 (-30.67%) | -$249,108,000 (-54.84%) | -$160,886,000 (-89.09%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $8,142,000 (-34.88%) | $12,504,000 (-37.29%) | $19,939,000 (-2.91%) | $20,536,000 (-3.21%) |
Debt Current | $1,188,000 (-72.76%) | $4,362,000 (-42.49%) | $7,585,000 (846.94%) | $801,000 (-72.35%) |
Debt Non-Current | $6,954,000 (-14.59%) | $8,142,000 (-34.09%) | $12,354,000 (-37.40%) | $19,735,000 (7.72%) |
Total Liabilities | $53,477,000 (121.91%) | $24,099,000 (-28.10%) | $33,518,000 (2.72%) | $32,631,000 (-21.56%) |
Liabilities Current | $27,261,000 (70.84%) | $15,957,000 (-24.44%) | $21,119,000 (65.28%) | $12,778,000 (-42.32%) |
Liabilities Non-Current | $26,216,000 (221.98%) | $8,142,000 (-34.33%) | $12,399,000 (-37.55%) | $19,853,000 (2.09%) |
XLO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $6,344,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $24,778,000 (-8.22%) | $26,997,000 (-9.85%) | $29,948,000 (25.54%) | $23,856,000 (123.94%) |
Research & Development Expense | $41,211,000 (-20.95%) | $52,136,000 (-11.93%) | $59,201,000 (15.65%) | $51,188,000 (16.57%) |
Operating Expenses | $66,926,000 (-15.43%) | $79,133,000 (-11.24%) | $89,149,000 (18.80%) | $75,044,000 (37.54%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$58,241,000 (23.77%) | -$76,404,000 (13.40%) | -$88,222,000 (-16.39%) | -$75,800,000 (-37.27%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$58,241,000 (23.77%) | -$76,404,000 (13.40%) | -$88,222,000 (-16.39%) | -$75,800,000 (-37.27%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$58,241,000 (23.77%) | -$76,404,000 (13.40%) | -$88,222,000 (-16.39%) | -$75,800,000 (-37.27%) |
Weighted Average Shares | $53,511,424 (94.61%) | $27,496,107 (0.38%) | $27,392,087 (388.59%) | $5,606,308 (970.34%) |
Weighted Average Shares Diluted | $53,511,424 (94.61%) | $27,496,107 (0.38%) | $27,392,087 (388.59%) | $5,606,308 (970.34%) |
Earning Before Interest & Taxes (EBIT) | -$58,241,000 (23.77%) | -$76,404,000 (13.40%) | -$88,222,000 (-16.39%) | -$75,800,000 (-37.27%) |
Gross Profit | $6,344,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Operating Income | -$60,582,000 (23.44%) | -$79,133,000 (11.24%) | -$89,149,000 (-18.80%) | -$75,044,000 (-37.54%) |
XLO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | -$36,000 (92.59%) | -$486,000 (73.97%) | -$1,867,000 (-69.73%) | -$1,100,000 (49.73%) |
Net Cash Flow from Financing | $29,196,000 (545.74%) | -$6,550,000 (-9392.75%) | -$69,000 (-100.03%) | $260,668,000 (2499.14%) |
Net Cash Flow from Operations | -$18,378,000 (73.22%) | -$68,620,000 (9.38%) | -$75,723,000 (6.23%) | -$80,751,000 (-123.74%) |
Net Cash Flow / Change in Cash & Cash Equivalents | $10,782,000 (114.25%) | -$75,656,000 (2.58%) | -$77,659,000 (-143.43%) | $178,817,000 (732.98%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | -$36,000 (92.59%) | -$486,000 (73.97%) | -$1,867,000 (-69.73%) | -$1,100,000 (49.73%) |
Issuance (Repayment) of Debt Securities | -$3,382,000 (49.91%) | -$6,752,000 (-7843.53%) | -$85,000 (22.73%) | -$110,000 (-11.11%) |
Issuance (Purchase) of Equity Shares | $32,578,000 (16027.72%) | $202,000 (1162.50%) | $16,000 (-99.99%) | $116,642,000 (73259.75%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $6,434,000 (-12.84%) | $7,382,000 (-12.37%) | $8,424,000 (69.91%) | $4,958,000 (282.56%) |
Depreciation Amortization & Accretion | $1,644,000 (-13.47%) | $1,900,000 (2.87%) | $1,847,000 (23.22%) | $1,499,000 (40.75%) |
XLO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 100.00% | - | - | - |
Profit Margin | -918.00% | - | - | - |
EBITDA Margin | -892.10% | - | - | - |
Return on Average Equity (ROAE) | -238.30% (-88.23%) | -126.60% (-94.47%) | -65.10% (56.13%) | -148.40% (-251.58%) |
Return on Average Assets (ROAA) | -73.20% (17.94%) | -89.20% (-69.58%) | -52.60% (11.74%) | -59.60% (46.55%) |
Return on Sales (ROS) | -918.00% | - | - | - |
Return on Invested Capital (ROIC) | 1397.00% (372.59%) | -512.50% (-18.61%) | -432.10% (-16.28%) | -371.60% (-40.28%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% |
Price to Earnings Ratio (P/E) | -0.88 (-342.42%) | -0.2 (76.29%) | -0.83 (29.42%) | -1.18 |
Price to Sales Ratio (P/S) | 8.05 | - | - | - |
Price to Book Ratio (P/B) | 2.38 (480.29%) | 0.41 (-41.20%) | 0.7 (-70.51%) | 2.37 |
Debt to Equity Ratio (D/E) | 3.04 (364.68%) | 0.65 (106.31%) | 0.32 (80.11%) | 0.18 (135.20%) |
Earnings Per Share (EPS) | -1.09 (60.79%) | -2.78 (13.66%) | -3.22 (76.18%) | -13.52 (87.18%) |
Sales Per Share (SPS) | 0.12 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Free Cash Flow Per Share (FCFPS) | -0.34 (86.31%) | -2.51 (11.30%) | -2.83 (80.60%) | -14.6 (80.02%) |
Book Value Per Share (BVPS) | 0.33 (-75.43%) | 1.34 (-65.28%) | 3.86 (-88.34%) | 33.08 (120.80%) |
Tangible Assets Book Value Per Share (TABVPS) | 1.33 (-40.07%) | 2.22 (-56.38%) | 5.08 (-86.94%) | 38.9 (-43.90%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | 0 (0%) | 1 (120.00%) | -5 |
Enterprise Value Over EBITDA (EV/EBITDA) | 0.22 (-47.78%) | 0.43 (-21.07%) | 0.54 (111.20%) | -4.83 |
Asset Turnover | 0.08 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Current Ratio | 2.21 (-26.72%) | 3.02 (-48.84%) | 5.89 (-62.81%) | 15.85 (1606.03%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$18,414,000 (73.35%) | -$69,106,000 (10.93%) | -$77,590,000 (5.21%) | -$81,851,000 (-113.83%) |
Enterprise Value (EV) | -$12,639,039 (60.28%) | -$31,817,900 (31.87%) | -$46,703,377 (-113.01%) | $358,852,168 |
Earnings Before Tax (EBT) | -$58,241,000 (23.77%) | -$76,404,000 (13.40%) | -$88,222,000 (-16.39%) | -$75,800,000 (-37.27%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$56,597,000 (24.03%) | -$74,504,000 (13.74%) | -$86,375,000 (-16.25%) | -$74,301,000 (-37.20%) |
Invested Capital | -$5,117,000 (-145.76%) | $11,182,000 (-30.28%) | $16,038,000 (-38.81%) | $26,212,000 (79.66%) |
Working Capital | $32,973,000 (2.50%) | $32,170,000 (-68.88%) | $103,377,000 (-45.52%) | $189,739,000 (12223.90%) |
Tangible Asset Value | $71,075,000 (16.66%) | $60,926,000 (-56.22%) | $139,165,000 (-36.18%) | $218,060,000 (500.44%) |
Market Capitalization | $41,979,961 (177.13%) | $15,148,100 (-79.50%) | $73,898,623 (-83.19%) | $439,503,168 |
Average Equity | $24,438,250 (-59.52%) | $60,373,500 (-55.47%) | $135,570,750 (165.46%) | $51,071,000 (190.54%) |
Average Assets | $79,553,750 (-7.13%) | $85,658,000 (-48.94%) | $167,764,500 (31.90%) | $127,188,500 (156.85%) |
Invested Capital Average | -$4,169,000 (-127.97%) | $14,906,750 (-26.99%) | $20,416,750 (0.08%) | $20,401,000 (-2.15%) |
Shares | 43,958,074 (59.60%) | 27,542,000 (0.26%) | 27,471,607 (0.01%) | 27,468,948 (3.01%) |
